Full-Time

Principal Scientist

Immunology

Posted on 8/15/2025

Stylus Medicine

Stylus Medicine

11-50 employees

In vivo genome editing for CAR-T

No salary listed

Cambridge, MA, USA

In Person

Category
Lab & Research (1)
Requirements
  • PhD in immunology, cancer biology, or a related field with 6+ years of relevant experience
  • Deep expertise in T cell biology, immuno-oncology, and/or innate immune cell function
  • Demonstrated experience with ex vivo T cell engineering (preferably non-viral) and CART cell functional assays and profiling
  • Ability to design and interpret complex immunological experiments to evaluate cellular uptake, engineering efficiency, immune activation, immune phenotypes, and cellular function in support of program advancement
  • Track record of developing candidate nomination data sets, translationally relevant in vitro models to support target validation, mechanism of action studies, and biomarker discovery
  • Demonstrated contributions to IND-enabling studies, including drafting or reviewing nonclinical sections of regulatory filings and supporting regulatory strategy
  • Strong leadership and project management skills; experience mentoring junior scientists and collaborating cross-functionally to advance pipeline programs
  • Track record of publications and/or patents in relevant fields
Responsibilities
  • Contribute to the development of a pipeline of products for in vivo CART applications by leading development candidate and IND supportive data generation
  • Lead the design and execution of in vitro studies to evaluate LNP-mediated delivery of genome engineering recombinases to primary human immune cells, with a focus on generation of CAR T cells
  • Establish in vitro pharmacology assays to determine dose-responsive transfection and integration efficiency, engineered cell phenotypic profiles, CART cell functional assessment, and genome integration impacts on CART cell function
  • Contribute immune biology support for development candidate nomination by integrating data from multi-parametric in vitro studies in close collaboration with LNP formulation, genome engineering, and in vivo pharmacology teams
  • Contribute to the design of translational workflows linking in vitro data to in vivo pharmacology and clinical hypotheses
  • Execute studies to support in vitro pharmacology data package for regulatory submissions
  • Prepare study reports and data summaries for regulatory submissions, including IND-enabling packages
  • Present findings in internal cross-functional meetings; contribute to external publications and scientific conferences, as needed
  • Mentor junior team members and contribute to strategic planning of immunology research efforts
Desired Qualifications
  • Experience with LNP technologies and familiarity with in vivo delivery approaches preferred
  • Familiarity with assessment of immune-related tolerability readouts is a plus

Stylus Medicine develops in vivo genetic medicines by combining engineered, therapeutic-grade recombinases with non-viral lipid nanoparticle (LNP) delivery. This platform enables sequence-specific genome integration to insert large genetic payloads directly inside a patient’s body, bypassing the complex steps of ex vivo cell modification. The initial focus is in oncology, delivering a recombinase and a CAR-encoding DNA payload to a patient’s T cells via LNP infusion, effectively turning the patient’s body into an in vivo CAR-T cell factory. The modular system can adapt CAR constructs to target different cancer antigens and holds potential for autoimmune and other genetic diseases beyond oncology. The company positions itself as an off-the-shelf, scalable genetic therapy approach that streamlines treatment workflows and broadens patient access by avoiding traditional ex vivo manufacturing.

Company Size

11-50

Company Stage

Series A

Total Funding

$85M

Headquarters

Cambridge, Massachusetts

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $85M in 2025 from RA Capital, Khosla, Lilly, and J&J.
  • Preclinical in vivo CAR-T data presented at ASGCT 2025.
  • Led by CEO Nuwaysir with 25+ years in cell therapy.

What critics are saying

  • Prime Medicine's PRIME Editing partners with BMS in January 2025.
  • Beam's base editing hits 40% efficiency in NHPs at ASGCT May 2025.
  • Arc licenses Hsu's IP exclusively to CRISPR Therapeutics February 2026.

What makes Stylus Medicine unique

  • Stylus combines engineered recombinases with LNP for in vivo genome integration.
  • Platform enables precise insertion of multi-kb payloads into T-cells directly.
  • Avoids ex vivo manufacturing complexities of traditional CAR-T therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Company News

The Pharma Letter
May 14th, 2025
Stylus Medicine launches with $85M funding

Stylus Medicine, a biotech company based in Cambridge, USA, has emerged from stealth mode with $85 million in funding.

Yahoo Finance
May 14th, 2025
Stylus Medicine launches with $85m to advance in vivo gene editing

Stylus will use the Eli Lilly and J&J-backed funds to advance its in vivo genetic medicines platform and develop its pipeline.

Fierce Biotech
May 13th, 2025
Stylus Medicine raises $85M for gene editing.

Stylus Medicine has emerged from stealth with $85 million in funding to develop next-gen in vivo genetic medicines. The financing includes a prior $40 million series A and a recent $45 million series A extension, with investors like RA Capital, Khosla Ventures, Eli Lilly, and J&J Innovation. Led by CEO Emile Nuwaysir, Stylus aims to simplify gene editing with a platform featuring recombinase technology. Preclinical data will be presented at the American Society of Gene & Cell Therapy meeting.

Endpoints News
May 12th, 2025
Stylus Medicine raises $85M for tech

Patrick Hsu's startup, Stylus Medicine, has launched with an ambitious goal to develop new gene insertion technologies beyond CRISPR. The company has successfully raised $85 million to support its development efforts.

Endpoints News
May 12th, 2025
Exclusive: Patrick Hsu startup launches, looks beyond CRISPR for gene insertion technology

Stylus Medicine, an ambitious startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes...

INACTIVE